{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:53:24Z","timestamp":1778028804372,"version":"3.51.4"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,12,6]],"date-time":"2016-12-06T00:00:00Z","timestamp":1480982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,12,6]],"date-time":"2016-12-06T00:00:00Z","timestamp":1480982400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The treatment of leishmaniasis still relies on drugs with potentially serious adverse effects. Herein, we tested a topical formulation of bacterial cellulose (BC) membranes containing Diethyldithiocarbamate (DETC), a superoxide dismutase 1 inhibitor. <jats:italic>Leishmania<\/jats:italic>-infected macrophages exposed to BC-DETC resulted in parasite killing, without pronounced toxic effects to host cells. This outcome was associated with lower SOD1 activity and higher production of superoxide and cytokine mediators. Topical application of BC-DETC significantly decreased lesion size, parasite load and the inflammatory response at the infection site, as well as the production of both IFN-\u03b3 and TNF. Combination of topical BC-DETC plus intraperitoneal Sb<jats:sup>v<\/jats:sup> also significantly reduced disease development and parasite load. The leishmanicidal effect of BC-DETC was extended to human macrophages infected with <jats:italic>L. braziliensis<\/jats:italic>, highlighting the feasibility of BC-DETC as a topical formulation for chemotherapy of cutaneous leishmaniasis caused by <jats:italic>L. braziliensis<\/jats:italic>.<\/jats:p>","DOI":"10.1038\/srep38330","type":"journal-article","created":{"date-parts":[[2016,12,6]],"date-time":"2016-12-06T10:20:06Z","timestamp":1481019606000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["DETC-based bacterial cellulose bio-curatives for topical treatment of cutaneous leishmaniasis"],"prefix":"10.1038","volume":"6","author":[{"given":"Fabiana S.","family":"Celes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eliane","family":"Trovatti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricardo","family":"Khouri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johan","family":"Van Weyenbergh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sidney J. L.","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valeria M.","family":"Borges","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hernane S.","family":"Barud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camila I.","family":"de Oliveira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,12,6]]},"reference":[{"key":"BFsrep38330_CR1","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1111\/j.1469-0691.2011.03635.x","volume":"17","author":"M den Boer","year":"2011","unstructured":"den Boer, M., Argaw, D., Jannin, J. & Alvar, J. Leishmaniasis impact and treatment access. Clin Microbiol Infect 17, 1471\u20131477 (2011).","journal-title":"Clin Microbiol Infect"},{"key":"BFsrep38330_CR2","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1590\/S1413-86702003000300009","volume":"7","author":"A Bittencourt","year":"2003","unstructured":"Bittencourt, A. et al. Post-kala-azar dermal leishmaniasis associated with AIDS. Braz J Infect Dis. 7, 229\u2013233 (2003).","journal-title":"Braz J Infect Dis."},{"key":"BFsrep38330_CR3","doi-asserted-by":"publisher","first-page":"e35671","DOI":"10.1371\/journal.pone.0035671","volume":"7","author":"J Alvar","year":"2012","unstructured":"Alvar, J. et al. Leishmaniasis worldwide and global estimates of its incidence. PLoS One 7, e35671 (2012).","journal-title":"PLoS One"},{"key":"BFsrep38330_CR4","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.pt.2003.09.008","volume":"19","author":"SL Croft","year":"2003","unstructured":"Croft, S. L. & Coombs, G. H. Leishmaniasis\u2013current chemotherapy and recent advances in the search for novel drugs. Trends Parasitol 19, 502\u2013508 (2003).","journal-title":"Trends Parasitol"},{"key":"BFsrep38330_CR5","doi-asserted-by":"crossref","unstructured":"Llanos-Cuentas, A. et al. Clinical and parasite species risk factors for pentavalent antimonial treatment failure in cutaneous leishmaniasis in Peru. Clin Infect Dis 46 (2008).","DOI":"10.1086\/524042"},{"key":"BFsrep38330_CR6","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1093\/jac\/dkn549","volume":"63","author":"C Annaloro","year":"2009","unstructured":"Annaloro, C. et al. Retrospective evaluation of amphotericin B deoxycholate toxicity in a single centre series of haematopoietic stem cell transplantation recipients. J Antimicrob Chemother 63, 625\u2013626 (2009).","journal-title":"J Antimicrob Chemother"},{"key":"BFsrep38330_CR7","doi-asserted-by":"publisher","first-page":"e912","DOI":"10.1371\/journal.pntd.0000912","volume":"4","author":"PR Machado","year":"2010","unstructured":"Machado, P. R. et al. Miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania braziliensis in Brazil: a randomized and controlled trial. PLoS Negl Trop Dis 4, e912 (2010).","journal-title":"PLoS Negl Trop Dis"},{"key":"BFsrep38330_CR8","doi-asserted-by":"publisher","first-page":"2525","DOI":"10.4049\/jimmunol.0802860","volume":"182","author":"R Khouri","year":"2009","unstructured":"Khouri, R. et al. IFN-beta impairs superoxide-dependent parasite killing in human macrophages: evidence for a deleterious role of SOD1 in cutaneous leishmaniasis. J Immunol 182, 2525\u2013253 (2009).","journal-title":"J Immunol"},{"key":"BFsrep38330_CR9","doi-asserted-by":"crossref","unstructured":"Khouri, R. et al. SOD1 plasma level as a biomarker for therapeutic failure in cutaneous leishmaniasis. J Infect Dis 210 (2014).","DOI":"10.1093\/infdis\/jiu087"},{"key":"BFsrep38330_CR10","doi-asserted-by":"crossref","first-page":"8983","DOI":"10.1016\/S0021-9258(19)52496-6","volume":"256","author":"D Cocco","year":"1981","unstructured":"Cocco, D., Calabrese, L., Rigo, A., Argese, E. & Rotilio, G. Re-examination of the reaction of diethyldithiocarbamate with the copper of superoxide dismutase. J Biol Chem 256, 8983\u20138986 (1981).","journal-title":"J Biol Chem"},{"key":"BFsrep38330_CR11","doi-asserted-by":"publisher","first-page":"e14394","DOI":"10.1371\/journal.pone.0014394","volume":"5","author":"R Khouri","year":"2010","unstructured":"Khouri, R. et al. DETC induces Leishmania parasite killing in human in vitro and murine in vivo models: a promising therapeutic alternative in Leishmaniasis. PLoS One 5, e14394 (2010).","journal-title":"PLoS One"},{"key":"BFsrep38330_CR12","doi-asserted-by":"publisher","first-page":"3358","DOI":"10.1002\/anie.200460587","volume":"44","author":"D Klemm","year":"2005","unstructured":"Klemm, D., Heublein, B., Fink, H.-P. & Bohn, A. Cellulose: Fascinating Biopolymer and Sustainable Raw Material. Angewandte Chemie International Edition 44, 3358\u20133393 (2005).","journal-title":"Angewandte Chemie International Edition"},{"key":"BFsrep38330_CR13","first-page":"107","volume":"47","author":"PR Chawla","year":"2009","unstructured":"Chawla, P. R., Bajaj, I. B., Survase, S. A. & Singhal, R. S. Microbial Cellulose: Fermentative Production and Applications. Food Technol. Biotechnol. 47, 107\u2013124 (2009).","journal-title":"Food Technol. Biotechnol."},{"key":"BFsrep38330_CR14","doi-asserted-by":"publisher","first-page":"5438","DOI":"10.1002\/anie.201001273","volume":"50","author":"D Klemm","year":"2011","unstructured":"Klemm, D. et al. Nanocelluloses: a new family of nature-based materials. Angew Chem Int Ed Engl 50, 5438\u20135466 (2011).","journal-title":"Angew Chem Int Ed Engl"},{"key":"BFsrep38330_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1021\/bm060620d","volume":"8","author":"WK Czaja","year":"2007","unstructured":"Czaja, W. K., Young, D. J., Kawecki, M. & Brown, R. M. Jr. The future prospects of microbial cellulose in biomedical applications. Biomacromolecules 8, 1\u201312 (2007).","journal-title":"Biomacromolecules"},{"key":"BFsrep38330_CR16","doi-asserted-by":"publisher","first-page":"4162","DOI":"10.1021\/bm201303r","volume":"12","author":"E Trovatti","year":"2011","unstructured":"Trovatti, E. et al. Biocellulose Membranes as Supports for Dermal Release of Lidocaine. Biomacromolecules 12, 4162\u20134168 (2011).","journal-title":"Biomacromolecules"},{"key":"BFsrep38330_CR17","first-page":"703024","volume":"2013","author":"S Barud Hda","year":"2013","unstructured":"Barud Hda, S. et al. Antimicrobial Brazilian Propolis (EPP-AF) Containing Biocellulose Membranes as Promising Biomaterial for Skin Wound Healing. Evid Based Complement Alternat Med 2013, 703024 (2013).","journal-title":"Evid Based Complement Alternat Med"},{"key":"BFsrep38330_CR18","doi-asserted-by":"publisher","first-page":"5827","DOI":"10.1128\/IAI.73.9.5827-5834.2005","volume":"73","author":"TR de Moura","year":"2005","unstructured":"de Moura, T. R. et al. Toward a novel experimental model of infection to study American cutaneous leishmaniasis caused by Leishmania braziliensis. Infect Immun 73, 5827\u20135834 (2005).","journal-title":"Infect Immun"},{"key":"BFsrep38330_CR19","doi-asserted-by":"crossref","first-page":"4144","DOI":"10.4049\/jimmunol.135.6.4144","volume":"135","author":"EM Carvalho","year":"1985","unstructured":"Carvalho, E. M. et al. Cell mediated immunity in American cutaneous and mucosal leishmaniasis. J Immunol 135, 4144\u20134148 (1985).","journal-title":"J Immunol"},{"key":"BFsrep38330_CR20","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1590\/S0100-879X1998000100020","volume":"31","author":"A Ribeiro-de-Jesus","year":"1998","unstructured":"Ribeiro-de-Jesus, A., Almeida, R. P., Lessa, H., Bacellar, O. & Carvalho, E. M. Cytokine profile and pathology in human leishmaniasis. Braz J Med Biol Res 31, 143\u2013148 (1998).","journal-title":"Braz J Med Biol Res"},{"key":"BFsrep38330_CR21","first-page":"399","volume":"123","author":"SL Croft","year":"2006","unstructured":"Croft, S. L., Seifert, K. & Yardley, V. Current scenario of drug development for leishmaniasis. Indian J Med Res 123, 399\u2013410 (2006).","journal-title":"Indian J Med Res"},{"key":"BFsrep38330_CR22","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1023\/A:1004775229149","volume":"35","author":"M Iguchi","year":"2000","unstructured":"Iguchi, M., Yamanaka, S. & Budhiono, A. Bacterial cellulose\u2014amasterpiece of nature\u2019s arts. N Mater Sci 35, 261\u2013270 (2000).","journal-title":"N Mater Sci"},{"key":"BFsrep38330_CR23","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.jss.2014.02.011","volume":"189","author":"M Scherner","year":"2014","unstructured":"Scherner, M. et al. In vivo application of tissue-engineered blood vessels of bacterial cellulose as small arterial substitutes: proof of concept? J Surg Res 189, 340\u2013347 (2014).","journal-title":"J Surg Res"},{"key":"BFsrep38330_CR24","doi-asserted-by":"publisher","first-page":"7423","DOI":"10.1007\/s00253-014-5819-z","volume":"98","author":"H Martinez Avila","year":"2014","unstructured":"Martinez Avila, H. et al. Biocompatibility evaluation of densified bacterial nanocellulose hydrogel as an implant material for auricular cartilage regeneration. Appl Microbiol Biotechnol 98, 7423\u20137435 (2014).","journal-title":"Appl Microbiol Biotechnol"},{"key":"BFsrep38330_CR25","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.molcatb.2007.12.021","volume":"54","author":"S-C Wu","year":"2008","unstructured":"Wu, S.-C. & Lia, Y.-K. Application of bacterial cellulose pellets in enzyme immobilization. Journal of Molecular Catalysis B: Enzymatic 54, 103\u2013108 (2008).","journal-title":"Journal of Molecular Catalysis B: Enzymatic"},{"key":"BFsrep38330_CR26","doi-asserted-by":"crossref","unstructured":"Trovatti, E. et al. Bacterial cellulose membranes applied in topical and transdermal delivery of lidocaine hydrochloride and ibuprofen: In vitro diffusion studies. International Journal of Pharmaceutics 83\u201387 (2012).","DOI":"10.1016\/j.ijpharm.2012.01.002"},{"key":"BFsrep38330_CR27","doi-asserted-by":"crossref","unstructured":"Cecilio, P. et al. Deception and manipulation: the arms of leishmania, a successful parasite. Front Immunol 5 (2014).","DOI":"10.3389\/fimmu.2014.00480"},{"key":"BFsrep38330_CR28","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s10570-013-0114-1","volume":"21","author":"NCS Silva","year":"2014","unstructured":"Silva, N. C. S. et al. Topical caffeine delivery using biocellulose membranes: a potential innovative system for cellulite treatment. Cellulose 21, 665\u2013674 (2014).","journal-title":"Cellulose"},{"key":"BFsrep38330_CR29","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1177\/0883911509102710","volume":"24","author":"YM Chen","year":"2009","unstructured":"Chen, Y. M. et al. In vitro cytotoxiciyty of bacterial cellulose scaffolds used for tissue-enginnered bone. Journal of Bioactive and compactible polymers 24, 137\u2013145 (2009).","journal-title":"Journal of Bioactive and compactible polymers"},{"key":"BFsrep38330_CR30","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1007\/s13273-010-0049-7","volume":"6","author":"S Jeong","year":"2010","unstructured":"Jeong, S. et al. Toxicologic evaluation of bacterial synthesized cellulose in endothelial cells and animals. Molecular & Cellular Toxicology 6, 370\u2013377 (2010).","journal-title":"Molecular & Cellular Toxicology"},{"key":"BFsrep38330_CR31","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s13206-013-7302-9","volume":"7","author":"G-D Kim","year":"2013","unstructured":"Kim, G.-D. et al. Evaluation of immunoreactivity of in vitro and in vivo models against bacterial synthesized cellulose to be used as a prosthetic biomaterial. BioChip Journal 7, 201\u2013209 (2013).","journal-title":"BioChip Journal"},{"key":"BFsrep38330_CR32","doi-asserted-by":"crossref","first-page":"4306","DOI":"10.4049\/jimmunol.145.12.4306","volume":"145","author":"FY Liew","year":"1990","unstructured":"Liew, F. Y., Li, Y. & Millott, S. Tumor necrosis factor-alpha synergizes with IFN-gamma in mediating killing of Leishmania major through the induction of nitric oxide. J Immunol 145, 4306\u20134310 (1990).","journal-title":"J Immunol"},{"key":"BFsrep38330_CR33","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.imbio.2008.01.003","volume":"213","author":"AW Ho","year":"2008","unstructured":"Ho, A. W., Wong, C. K. & Lam, C. W. Tumor necrosis factor-alpha up-regulates the expression of CCL2 and adhesion molecules of human proximal tubular epithelial cells through MAPK signaling pathways. Immunobiology 213, 533\u2013544 (2008).","journal-title":"Immunobiology"},{"key":"BFsrep38330_CR34","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1165\/ajrcmb.24.6.4228","volume":"24","author":"S Corda","year":"2001","unstructured":"Corda, S., Laplace, C., Vicaut, E. & Duranteau, J. Rapid reactive oxygen species production by mitochondria in endothelial cells exposed to tumor necrosis factor-alpha is mediated by ceramide. Am J Respir Cell Mol Biol 24, 762\u2013768 (2001).","journal-title":"Am J Respir Cell Mol Biol"},{"key":"BFsrep38330_CR35","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1042\/bj2630539","volume":"263","author":"B Meier","year":"1989","unstructured":"Meier, B. et al. Human fibroblasts release reactive oxygen species in response to interleukin-1 or tumour necrosis factor-alpha. Biochem J 263, 539\u2013545 (1989).","journal-title":"Biochem J"},{"key":"BFsrep38330_CR36","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1093\/infdis\/jiu013","volume":"209","author":"FO Novais","year":"2014","unstructured":"Novais, F. O. et al. Human classical monocytes control the intracellular stage of Leishmania braziliensis by reactive oxygen species. J Infect Dis 209, 1288\u20131296 (2014).","journal-title":"J Infect Dis"},{"key":"BFsrep38330_CR37","doi-asserted-by":"publisher","first-page":"e3275","DOI":"10.1371\/journal.pntd.0003275","volume":"8","author":"DM Santos","year":"2014","unstructured":"Santos, D. M. et al. Chemotherapeutic Potential of 17-AAG against Cutaneous Leishmaniasis Caused by Leishmania (Viannia) braziliensis. PLoS Negl Trop Dis 8, e3275 (2014).","journal-title":"PLoS Negl Trop Dis"},{"key":"BFsrep38330_CR38","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.ijpara.2012.05.006","volume":"42","author":"S Falcao","year":"2012","unstructured":"Falcao, S. et al. The presence of Tregs does not preclude immunity to reinfection with Leishmania braziliensis. Int J Parasitol 42, 771\u2013780 (2012).","journal-title":"Int J Parasitol"},{"key":"BFsrep38330_CR39","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1111\/j.1600-065X.2006.00432.x","volume":"213","author":"N Peters","year":"2006","unstructured":"Peters, N. & Sacks, D. Immune privilege in sites of chronic infection: Leishmania and regulatory T cells. Immunol Rev 213, 159\u2013179 (2006).","journal-title":"Immunol Rev"},{"key":"BFsrep38330_CR40","doi-asserted-by":"publisher","first-page":"5122","DOI":"10.4049\/jimmunol.166.8.5122","volume":"166","author":"S Mendez","year":"2001","unstructured":"Mendez, S. et al. The potency and durability of DNA- and protein-based vaccines against Leishmania major evaluated using low-dose, intradermal challenge. J Immunol 166, 5122\u20135128 (2001).","journal-title":"J Immunol"},{"key":"BFsrep38330_CR41","doi-asserted-by":"publisher","first-page":"6967","DOI":"10.4049\/jimmunol.167.12.6967","volume":"167","author":"JE Uzonna","year":"2001","unstructured":"Uzonna, J. E., Wei, G., Yurkowski, D. & Bretscher, P. Immune elimination of Leishmania major in mice: implications for immune memory, vaccination, and reactivation disease. J Immunol 167, 6967\u20136974 (2001).","journal-title":"J Immunol"},{"key":"BFsrep38330_CR42","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1038\/nature01152","volume":"420","author":"Y Belkaid","year":"2002","unstructured":"Belkaid, Y., Piccirillo, C. A., Mendez, S., Shevach, E. M. & Sacks, D. L. CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity. Nature 420, 502\u2013507 (2002).","journal-title":"Nature"},{"key":"BFsrep38330_CR43","doi-asserted-by":"publisher","first-page":"7068287","DOI":"10.1155\/2016\/7068287","volume":"2016","author":"AK Carvalho","year":"2016","unstructured":"Carvalho, A. K. et al. Differential Recruitment of Dendritic Cells Subsets to Lymph Nodes Correlates with a Protective or Permissive T-Cell Response during Leishmania (Viannia) Braziliensis or Leishmania (Leishmania) Amazonensis Infection. Mediators Inflamm 2016, 7068287 (2016).","journal-title":"Mediators Inflamm"},{"key":"BFsrep38330_CR44","doi-asserted-by":"publisher","first-page":"e540","DOI":"10.1371\/journal.pntd.0000540","volume":"3","author":"ER Sharlow","year":"2009","unstructured":"Sharlow, E. R. et al. Identification of potent chemotypes targeting Leishmania major using a high-throughput, low-stringency, computationally enhanced, small molecule screen. PLoS Negl Trop Dis 3, e540 (2009).","journal-title":"PLoS Negl Trop Dis"},{"key":"BFsrep38330_CR45","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/1752-0509-6-27","volume":"6","author":"AK Chavali","year":"2012","unstructured":"Chavali, A. K. et al. Metabolic network analysis predicts efficacy of FDA-approved drugs targeting the causative agent of a neglected tropical disease. BMC Syst Biol 6, 27 (2012).","journal-title":"BMC Syst Biol"},{"key":"BFsrep38330_CR46","doi-asserted-by":"publisher","first-page":"6734","DOI":"10.1128\/IAI.70.12.6734-6740.2002","volume":"70","author":"O Bacellar","year":"2002","unstructured":"Bacellar, O. et al. Up-regulation of Th1-type responses in mucosal leishmaniasis patients. Infect Immun 70, 6734\u20136740 (2002).","journal-title":"Infect Immun"},{"key":"BFsrep38330_CR47","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.imlet.2005.06.004","volume":"101","author":"LR Antonelli","year":"2005","unstructured":"Antonelli, L. R. et al. Activated inflammatory T cells correlate with lesion size in human cutaneous leishmaniasis. Immunol Lett 101, 226\u2013230 (2005).","journal-title":"Immunol Lett"},{"key":"BFsrep38330_CR48","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1292\/jvms.10-0239","volume":"73","author":"K Kanai","year":"2011","unstructured":"Kanai, K. et al. Anti-inflammatory potency of oral disulfiram compared with dexamethasone on endotoxin-induced uveitis in rats. J Vet Med Sci 73, 517\u2013520 (2011).","journal-title":"J Vet Med Sci"},{"key":"BFsrep38330_CR49","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.4049\/jimmunol.170.6.2993","volume":"170","author":"M Marikovsky","year":"2003","unstructured":"Marikovsky, M., Ziv, V., Nevo, N., Harris-Cerruti, C. & Mahler, O. Cu\/Zn superoxide dismutase plays important role in immune response. J Immunol 170, 2993\u20133001 (2003).","journal-title":"J Immunol"},{"key":"BFsrep38330_CR50","doi-asserted-by":"publisher","first-page":"571242","DOI":"10.4061\/2011\/571242","volume":"2011","author":"AK Haldar","year":"2011","unstructured":"Haldar, A. K., Sen, P. & Roy, S. Use of antimony in the treatment of leishmaniasis: current status and future directions. Molecular biology international 2011, 571242\u2013571242 (2011).","journal-title":"Molecular biology international"},{"key":"BFsrep38330_CR51","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1097\/QCO.0b013e32833fca9d","volume":"23","author":"PL Olliaro","year":"2010","unstructured":"Olliaro, P. L. Drug combinations for visceral leishmaniasis. Curr Opin Infect Dis 23, 595\u2013602 (2010).","journal-title":"Curr Opin Infect Dis"},{"key":"BFsrep38330_CR52","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1093\/jac\/dkv495","volume":"71","author":"CT Trinconi","year":"2016","unstructured":"Trinconi, C. T., Reimao, J. Q., Coelho, A. C. & Uliana, S. R. Efficacy of tamoxifen and miltefosine combined therapy for cutaneous leishmaniasis in the murine model of infection with Leishmania amazonensis. J Antimicrob Chemother 71, 1314\u20131322 (2016).","journal-title":"J Antimicrob Chemother"},{"key":"BFsrep38330_CR53","doi-asserted-by":"publisher","first-page":"2608","DOI":"10.1128\/AAC.01315-13","volume":"58","author":"CT Trinconi","year":"2014","unstructured":"Trinconi, C. T., Reimao, J. Q., Yokoyama-Yasunaka, J. K., Miguel, D. C. & Uliana, S. R. Combination therapy with tamoxifen and amphotericin B in experimental cutaneous leishmaniasis. Antimicrob Agents Chemother 58, 2608\u20132613 (2014).","journal-title":"Antimicrob Agents Chemother"},{"key":"BFsrep38330_CR54","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1371\/journal.pntd.0000432","volume":"3","author":"A Ben Salah","year":"2009","unstructured":"Ben Salah, A. et al. WR279,396, a third generation aminoglycoside ointment for the treatment of Leishmania major cutaneous leishmaniasis: a phase 2, randomized, double blind, placebo controlled study. PLoS Negl Trop Dis 3, 5 (2009).","journal-title":"PLoS Negl Trop Dis"},{"key":"BFsrep38330_CR55","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1056\/NEJMoa1202657","volume":"368","author":"A Ben Salah","year":"2013","unstructured":"Ben Salah, A. et al. Topical paromomycin with or without gentamicin for cutaneous leishmaniasis. N Engl J Med 368, 524\u2013532 (2013).","journal-title":"N Engl J Med"},{"key":"BFsrep38330_CR56","doi-asserted-by":"publisher","first-page":"147","DOI":"10.4269\/ajtmh.2002.66.147","volume":"66","author":"JM Soto","year":"2002","unstructured":"Soto, J. M. et al. Treatment of cutaneous leishmaniasis with a topical antileishmanial drug (WR279396): phase 2 pilot study. Am J Trop Med Hyg 66, 147\u2013151 (2002).","journal-title":"Am J Trop Med Hyg"},{"key":"BFsrep38330_CR57","doi-asserted-by":"publisher","first-page":"557","DOI":"10.4269\/ajtmh.12-0736","volume":"89","author":"N Sosa","year":"2013","unstructured":"Sosa, N. et al. Randomized, double-blinded, phase 2 trial of WR 279,396 (paromomycin and gentamicin) for cutaneous leishmaniasis in Panama. Am J Trop Med Hyg 89, 557\u2013563 (2013).","journal-title":"Am J Trop Med Hyg"},{"key":"BFsrep38330_CR58","unstructured":"UNESP. Ribeiro, S. J. B. H., de Oliveira, C. I., Celes, F. S. & Borges, V. M. Nanocomp\u00f3sitos de biocelulose e seu uso (2014)."},{"key":"BFsrep38330_CR59","doi-asserted-by":"publisher","first-page":"e1003504","DOI":"10.1371\/journal.ppat.1003504","volume":"9","author":"FO Novais","year":"2013","unstructured":"Novais, F. O. et al. Cytotoxic T cells mediate pathology and metastasis in cutaneous leishmaniasis. PLoS Pathog 9, e1003504 (2013).","journal-title":"PLoS Pathog"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep38330.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep38330","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep38330.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T00:56:29Z","timestamp":1672880189000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep38330"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,6]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,12,23]]}},"alternative-id":["BFsrep38330"],"URL":"https:\/\/doi.org\/10.1038\/srep38330","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,6]]},"assertion":[{"value":"17 August 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"38330"}}